4//SEC Filing
Haas Jason 4
Accession 0000950170-24-105995
CIK 0001556263other
Filed
Sep 11, 8:00 PM ET
Accepted
Sep 12, 5:00 PM ET
Size
8.7 KB
Accession
0000950170-24-105995
Insider Transaction Report
Form 4
Haas Jason
Chief Financial Officer
Transactions
- Purchase
Common Stock
2024-09-12$1.68/sh+45,344$76,006→ 124,552 total - Purchase
Common Stock
2024-09-10$1.55/sh+35,363$54,788→ 59,915 total - Purchase
Common Stock
2024-09-11$1.58/sh+19,293$30,446→ 79,208 total
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.50 to $1.57, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.55 to $1.60, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- [F3]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.62 to $1.69, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Documents
Issuer
Syros Pharmaceuticals, Inc.
CIK 0001556263
Entity typeother
Related Parties
1- filerCIK 0001883821
Filing Metadata
- Form type
- 4
- Filed
- Sep 11, 8:00 PM ET
- Accepted
- Sep 12, 5:00 PM ET
- Size
- 8.7 KB